Sánchez-Ríos CP, Rodríguez-Cid JR, Martínez-Barrera LM, Santillán-Doherty P, Alatorre-Alexander JA

Language: Spanish
References: 7
Page: 26-30
PDF size: 213.95 Kb.

ABSTRACT

Introduction: The treatment of lung cancer currently follows a model that is governed by the selection of patients according to the presence of oncogenic abnormalities. The ALK gene is present in 3 to 7% of patients with non-small cell lung cancer (NSCLC) and confers sensitivity to ALK inhibitors. Objective: To describe the clinical and tomographic behavior of patients with ALK positive lung cancer in INER. Material and methods: A retrospective observational study of patients with lung cancer from January 2013 to August 2018. A review of clinical and radiological records was made, with registration of sociodemographic, clinical and molecular variables. Results: A cohort was analyzed from 2013 to 2018 with a total of 751 patients diagnosed with lung cancer. The CPCNP was the most frequent with 93.74% (n = 704). The adenocarcinoma was found in 86% (n = 606). ALK rearrangement was reported in 3.3% (n = 20). The majority were 65% female (n = 13), the average age was 58 ± 2.4 years, smoking 40% (n = 8). Of the patients who never smoked, 92% (n = 11) reported exposure to biomass. In 25% (n = 5) COPD was documented. The tomographic patterns were: mass in 70% (n = 14), pleural thickening with pleural effusion in 20% (n = 4) and micronodular pattern in 10% (n = 2). Conclusions: A clinical phenotype and behavior different to the rest of patients with NSCLC is demonstrated in ALK positive patients.

REFERENCES

1. Kwak E, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-1703. doi: 10.1056/NEJMoa1006448

2. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16(22):5581-5590. doi: 10.1158/1078-0432.CCR-10-0851

3. Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer 2016;102:122-134. doi: 10.1016/j.lungcan.2016.10.010

4. Tanaka T, Matsuoka M, Sutani A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 2010;126(3):651-655. doi: 10.1002/ijc.24746

5. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31(8):1105-1111. doi: 10.1200/JCO.2012.44.5353

6. Sánchez-Ríos CP, Rodríguez-Cid JR, Martínez-Barrera LM, Santillán-Doherty P, Alatorre-Alexander JA. Descripción clínico-epidemiológica y molecular del cáncer de pulmón en un centro de referencia nacional. Neumol Cir Torax 2019;78(4):356-362. https://dx.doi.org/10.35366/NT194D

7. Yamamoto S, Korn RL, Oklu R, et al. ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology 2014;272(2):568-576. doi: 10.1148/radiol.14140789